Brief: PCI Biotech Extends Preclinical Research Collaboration Agreement With Pharma Company
18/12/2018 13:58
Dec 18 (Reuters) - PCI Biotech Holding ASA PCIB.OL :
* REG-PCI BIOTECH: EXTENSION OF PRECLINICAL RESEARCH
COLLABORATION
AGREEMENT WITH A TOP-10 LARGE PHARMA COMPANY
*
* EXTENDED EVALUATION PERIOD SPANS OVER 6 MONTHS, UNTIL END
OF
JUNE 2019, AND MAY BE FURTHER EXTENDED
Source text for Eikon: ID:nGNE94x6w
Further company coverage: PCIB.OL
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 587720920;))
Recent news on PCI Biotech Holding ASA
See all newsBrief: Euronext Oslo Børs To Delist PCI Biotech Holding Shares
Brief: Euronext Oslo Børs Gets Application From PCI Biotech Holding For Delisting
Brief: PCI Biotech Holding Board Proposes Dissolution, Delisting
Brief: Oslo Bors: PCI Biotech Holding Is Placed In Recovery Box
Brief: PCI Biotech Says Co Initiates Process To Evaluate Opportunity For Structured Wind-Up Process